抗凝治疗改善肝硬化合并门静脉血栓患者的生存:IMPORTAL竞争风险荟萃分析
该个体患者数据荟萃分析纳入5项研究共500例肝硬化合并门静脉血栓患者,205例(41%)接受抗凝治疗,295例未接受。以肝移植为竞争事件的竞争风险模型显示,抗凝降低全因死亡率(校正亚分布风险比0.59;95%CI 0.49-0.70),且再通率更高(校正比值比3.45;95%CI 2.22-5.36),但非门静脉高压相关出血率显著增加。
要点
- 抗凝降低肝硬化合并门静脉血栓患者全因死亡率,校正亚分布风险比0.59(95%CI 0.49-0.70)。
- 抗凝组再通率更高,校正比值比3.45(95%CI 2.22-5.36)。
- 抗凝组非门静脉高压相关出血率显著高于未治疗组。
核心结论
- 抗凝降低肝硬化合并门静脉血栓患者全因死亡率,且独立于再通,但以增加非门静脉高压相关出血为代价。
- 作者认为,门静脉血栓可能识别出一组可从长期抗凝获益的肝硬化患者。
研究设计与样本
- 个体患者数据荟萃分析,从PubMed、Embase和Cochrane数据库(截至2020年6月)筛选比较抗凝与不治疗的肝硬化合并门静脉血栓研究(PROSPERO注册号CRD42020140026)。
- 纳入5项研究共500例患者,205例(41%)接受抗凝治疗,295例未接受。
- 主要结局采用以肝移植为竞争事件的竞争风险模型一步法荟萃分析,并校正临床相关混杂因素;再通采用多水平混合效应逻辑回归模型。
主要发现
- 抗凝降低全因死亡率(校正亚分布风险比0.59;95%CI 0.49-0.70),独立于血栓严重程度和再通。
- 抗凝对全因死亡率的效应与肝脏相关死亡率降低一致。
- 抗凝组再通率高于未治疗组(校正比值比3.45;95%CI 2.22-5.36)。
- 抗凝组非门静脉高压相关出血率显著高于未治疗组。
关键数值与推荐
- 全因死亡率:校正亚分布风险比0.59(95%CI 0.49-0.70),抗凝组 vs 未治疗组。
- 再通率:校正比值比3.45(95%CI 2.22-5.36),抗凝组 vs 未治疗组。
- 非门静脉高压相关出血率:抗凝组显著高于未治疗组。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,门静脉血栓可能识别出一组可从长期抗凝获益的肝硬化患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Previous meta-analyses demonstrated the safety and efficacy of anticoagulation in the recanalization of portal vein thrombosis in patients with cirrhosis. Whether this benefit translates into improved survival is unknown. We conducted an individual patient data (IPD) meta-analysis to assess the effect of anticoagulation on all-cause mortality in patients with cirrhosis and portal vein thrombosis. METHODS: In this IPD meta-analysis, we selected studies comparing anticoagulation vs. no treatment in patients with cirrhosis and portal vein thrombosis from PubMed, Embase, and Cochrane databases (until June 2020) (PROSPERO no.: CRD42020140026). IPD were subsequently requested from authors. The primary outcome - the effect of anticoagulation on all-cause mortality - was assessed by a one-step meta-analysis based on a competing-risk model with liver transplantation as the competing event. The model was adjusted for clinically relevant confounders. A multilevel mixed-effects logistic regression model was used to determine the effect of anticoagulation on recanalization. RESULTS: Individual data on 500 patients from five studies were included; 205 (41%) received anticoagulation and 295 did not. Anticoagulation reduced all-cause mortality (adjusted subdistribution hazard ratio 0.59; 95% CI 0.49-0.70), independently of thrombosis severity and recanalization. The effect of anticoagulation on all-cause mortality was consistent with a reduction in liver-related mortality. The recanalization rate was higher in the anticoagulation arm (adjusted odds ratio 3.45; 95% CI 2.22-5.36). The non-portal-hypertension-related bleeding rate was significantly greater in the anticoagulation group. CONCLUSIONS: Anticoagulation reduces all-cause mortality in patients with cirrhosis and portal vein thrombosis independently of recanalization, but at the expense of increasing non-portal hypertension-related bleeding. PROSPERO REGISTRATION NUMBER: CRD42020140026. IMPACT AND IMPLICATIONS: Anticoagulation is effective in promoting recanalization of portal vein thrombosis in patients with cirrhosis, but whether this benefit translates into improved survival is controversial. Our individual patient data meta-analysis based on a competing-risk model with liver transplantation as the competing event shows that anticoagulation reduces all-cause mortality in patients with cirrhosis and portal vein thrombosis independently of recanalization. According to our findings, portal vein thrombosis may identify a group of patients with cirrhosis that benefit from long-term anticoagulation.
引用
- Guerrero A, Campo LD, Piscaglia F, et al. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis. J Hepatol. 2023. PMID: 36858157. doi:10.1016/j.jhep.2023.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。